Article Text

Download PDFPDF

AB0693 Patients with chronic inflammatory arthropathies treated with golimumab achieve a higher serum level of drug if used as the first or second biological drug
  1. J Rosas1,
  2. M Marco-Mingot2,
  3. JM Senabre-Gallego1,
  4. F Llinares-Tello2,
  5. A Pons1,
  6. X Barber3,
  7. G Santos-Soler1,
  8. E Salas1,
  9. C Cano1,
  10. M Lorente1,
  11. M Sanchís-Selfa3,
  12. J Molina2,
  13. M García-Carrasco4,
  14. on behalf of AIRE-MB Group
  1. 1Rheumatology Department
  2. 2Laboratory Department, Hospital Marina Baixa, Villajoyosa (Alicante)
  3. 3CIO, Universidad Miguel Hernández, Elche, Spain
  4. 4Rheumatology Department, Universidad Autόmoma de Puebla, Puebla, Mexico


Objectives To know the influence of the order of introduction of Golimumab (GLM), on clinical efficacy in ankylosing spondylitis (AS), psoriatic arthritis (PSA) and rheumatoid arthritis (RA).

Methods A prospective, observational study, in 46 consecutive patients with AS, APS and RA, treated with GLM. Data: epidemiological, concomitant DMARD, time of disease evolution, HLA-B27, RF and ACPA; from GLM: order of introduction, time in treatment, serum level and anti-GLM Ab. The clinical response was assessed in AS patients using BASDAI, BASFI, ASDAS-VSG. In patients with RA or peripheral APS, DAS28-VSG, DAS28-PCR and SDAI. Serum levels of GLM and anti-GLM Ab were determined by ELISA (Progenika, Grifols SA, Spain). Serum cutoff levels for serum GLM levels: 36 ng/mL and for anti-GLM Ab: UA>20 AU/mL. Samples were extracted just prior GLM administration (trough level) and stored frozen at -80°C until analysis.

Results Of 33 (72%) AS patients: 52% were males, mean age 53±12 years, mean BMI 28±4, disease mean evolution 16±12 years and in GLM: 1.3±1.1 years, 30% received DMARD, being GLM the first anti-TNF in 25%, second 37%, third 25% and fourth in 13%. The mean GLM level was 0.77±0.62 mg/mL and the prevalence of anti-GLM antibodies was 6%. In the 5 patients with RA and 8 with APS: 23% were men, mean age of 55±11 years, mean BMI 28±6, mean disease evolution of 10.5±8 years and in GLM of 2±1.5 years, the 85% of patients received DMARD, being GLM the first anti-TNF in 31%, second 15%, third 31% and fourth 23%. The mean GLM level was 0.703±0.53 mg/L. No anti-GLM Ab were detected.

Table 1.

Characteristics of patients with receiving GLM, according to the order of introduction

Conclusions 1. The overall prevalence of anti-GLM Ab was 6% and 17% in AS patients. Not detecting in patients with RA or PSA. 2. Serum GLM level was higher among the patients receiving it as the 1st or 2nd anti-TNF. 3. In AS GLM as 3rd or 4th anti-TNF were able to achieve clinical remission, similar to that achieved as 1st or 2nd drug.

Acknowledgements The study was supported by a grant from the Fundaciόn Española de Reumatología (FVR/2012) and the Asociaciόn para la Investigaciόn en Reumatología de la Marina Baixa (AIRE-MB).

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.